Blood Pressure in Migraine Patients Treated With Monoclonal Anti-CGRP (receptor) Antibodies: A Prospective Follow-up Study
Source : https://n.neurology.org/content/early/2022/10/04/WNL.0000000000201008
Background and Objectives: Anti-CGRP (receptor) antibodies are approved as preventive treatment for migraine. Recent concerns have been raised after a retrospective analysis of post-marketing case reports of elevated BP associated...
Discussion: The mean systolic and diastolic BP increased after anti-CGRP (receptor) antibodies were started. The majority of patients remained within the normal blood pressure limits, but some patients required antihypertensive treatment. Physicians should be aware that people with migraine may be at risk to develop hypertension when treated...
-
Huma Sheikh, CEO, NY Neurology Medicine, PC3yrImportant to keep this in mind.
-
Dr Hamid3yrPhysicians should be aware that people with migraine may be at risk of developing hypertension when treated with anti-CGRP (receptor) antibodies
Show More Comments
Inpatient Constipation Among Migraine Patients Prescribed Anti-calcitonin Gene-Related Peptide Monoclonal Antibodies and Standard of Care Antiepileptic Drugs: A Retrospective Cohort Study in a United States Electronic Health Record Database - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/36203078/
doi: 10.1007/s40122-022-00440-7. Online ahead of print. 1 Optum, 1325 Boylston Street, 11th Floor, Boston, MA, 02215, USA. [email protected]. 2 Optum, 1325 Boylston Street, 11th Floor, Boston, MA, 02215, USA. 3...
Conclusion: Patients initiating erenumab had similar risk of inpatient constipation within 90 days of treatment initiation versus patients initiating other CGRP mAbs, and lower risk versus patients initiating AEDs. These findings provide context to events observed during post-marketing surveillance.
-
Huma Sheikh, CEO, NY Neurology Medicine, PC3yrThat can be a common side effect.
-
Dr Hamid3yrInteresting article about Patients initiating erenumab and side Effects such as constipation
Rimegepant for the treatment of migraine | Published in Health Psychology Research
By Amnon A. Berger, Ariel Winnick & 13 more. It is a part of a growing arsenal in migraine treatment, and may present the silver bullet for treatment of this...
Conclusion/Relevance: Rimegepant, a second-generation gepant, has shown efficacy in several clinical trials in treating acute migraine. Ongoing trials are also evaluating its role in migraine prophylaxis, and results are promising. It is also generally safer for use than existing options, does not appear to increase the chance of developing...
-
Huma Sheikh, CEO, NY Neurology Medicine, PC3yrMOre medications acutely are needed.
-
Dr Hamid3yrMigraine is a common form of primary headache, affecting up to 1 in every 6 Americans.
Telemedicine for neurologic diseases: A systematic review and meta-analysis - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/36256522/
doi: 10.1111/ene.15599. Online ahead of print. 1 Canary Islands Health Research Institute Foundation (FIISC), Tenerife, Spain. 2 Evaluation Unit (SESCS), Canary Islands Health Service (SCS), Tenerife, Spain. 3 The Spanish...
Conclusions: Well-designed and executed RCTs are needed to confirm our findings on stroke and to have more scientific evidence available for the other neurologic diseases.
-
Huma Sheikh, CEO, NY Neurology Medicine, PC3yrThis is a great article.
-
Dr Hamid3yrInteresting article on review and effectiveness and safety of telemedicine
Assessment of the relative effectiveness of erenumab compared with onabotulinumtoxinA for the prevention of chronic migraine - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/36189948/
Objective : To assess the available clinical and economic evidence of erenumab vs onabotulinumtoxinA for chronic migraine (CM) and present de-novo indirect treatment comparisons (ITCs) based on available clinical trial...
Conclusion: These findings suggest directional benefits (although not reaching the threshold of statistical significance) associated with erenumab vs onabotulinumtoxinA for the preventive treatment of CM. Evidence from this study may inform healthcare stakeholders in treatment selection and optimization for patients with CM.
-
Dr Hamid3yrInteresting article- to assess the available clinical and economic evidence of erenumab vs onabotulinumtoxinA for chronic migraine (CM)
-
Huma Sheikh, CEO, NY Neurology Medicine, PC3yrHead to head are def needed.